TaiMed Biologics Inc. (4147)

Overview

TaiMed Biologics Inc. is a distinguished biotechnology entity dedicated to the advancement, production, and commercialization of medications aimed at the treatment and prevention of infectious diseases. Established in 2007 and having its headquarters in Taipei, Taiwan, the company has carved a notable niche in the realm of HIV-1 infection treatment through its innovative therapeutic solutions. By harnessing the potential of biotechnology, TaiMed Biologics is at the forefront of developing cutting-edge drugs that promise to transform the landscape of infectious disease management.

Products and Services

• Ibalizumab (TMB-355) Intravenous Infusion

A pioneering humanized monoclonal antibody designed for the treatment of HIV-1 infection, Ibalizumab represents a significant breakthrough in the management of this chronic disease. By targeting and neutralizing the mechanisms through which HIV invades human cells, this intravenous infusion offers a new horizon of hope for patients grappling with HIV-1.

• TMB-355 Intravenous Push

This variant of the TMB-355 formulation is developed as an intravenous push, intended to streamline the administration process for treating HIV-1 infection. Sharing the same base as Ibalizumab, it underscores the company's commitment to improving the patient experience and accessibility of HIV-1 treatments.

• TMB-355 Intramuscular Injection

Currently in Phase III clinical trials, the TMB-355 Intramuscular Injection is another formulation of the humanized monoclonal antibody targeting HIV-1 infections. Administered through an intramuscular route, this version of TMB-355 is geared towards enhancing the convenience and efficacy of treatment for patients.

• TMB-365

An anti-CD4 recombinant humanized monoclonal antibody, TMB-365 has successfully completed Phase I clinical trials. It is designed to target a different aspect of the HIV infection pathway, providing a novel approach to treating HIV infections. Its progress signifies the continual efforts of TaiMed Biologics to diversify and strengthen its portfolio of HIV treatment options.

• TMB-365/TMB-380

A combination of neutralizing HIV-1 antibodies, this innovative solution is part of TaiMed Biologics' continuous endeavor to combat HIV more effectively. By combining different mechanisms of action, TMB-365/TMB-380 aims to offer a more robust defense against HIV-1, showcasing the company's dedication to leading-edge research and development in the biotechnology sector.